Physician profile
Sandhya Shukla
NPI 1821220336
$9,453.06
in general payments reported to CMS, 2019-2025
30 companies · $3,230 in 2025
The $3,230 reported for 2025 was more than what 87% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $268 · 2020: $247 · 2021: $1,011 · 2022: $1,226 · 2023: $1,518 · 2024: $1,953 · 2025: $3,230.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,572 · Travel and Lodging: $1,062 · Education: $27.75 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $20.00 · Grant: $20.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,571.79 |
| Travel and Lodging | $1,061.52 |
| Education | $27.75 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $20.00 |
| Grant | $20.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,798.77 | 2019-2025 | Linzess, Skyrizi, Viberzi |
| Medtronic, INC. | $1,097.35 | 2025 | Endoflip |
| Janssen Biotech, INC. | $1,023.47 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Celgene Corporation | $774.17 | 2021-2024 | Zeposia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $765.81 | 2019-2025 | Xifaxan, Plenvu, Trulance |
| Madrigal Pharmaceuticals | $582.65 | 2024-2025 | Rezdiffra, Resmetirom |
| Genzyme Corporation | $491.31 | 2022-2025 | |
| Pfizer INC. | $396.67 | 2020-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $353.02 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Redhill Biopharma INC. | $250.01 | 2020-2024 | Talicia, Aemcolo, Movantik |
| Lilly USA, LLC | $246.05 | 2024-2025 | Omvoh |
| Gilead Sciences, INC. | $190.40 | 2019-2025 | |
| Qol Medical, LLC | $183.20 | 2019-2024 | Sucraid, Sucraid |
| Phathom Pharmaceuticals, INC. | $174.39 | 2024-2025 | Voquezna |
| Ardelyx, INC. | $147.97 | 2023-2025 | Ibsrela |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $142.02 | 2023-2025 | Dupixent |
| Janssen Scientific Affairs, LLC | $124.99 | 2022 | |
| Daiichi Sankyo INC. | $123.13 | 2021-2024 | Injectafer |
| Novo Nordisk INC | $119.63 | 2023 | Wegovy |
| Merck Sharp & Dohme LLC | $84.27 | 2019-2023 | Dificid |
| Braintree Laboratories, INC. | $78.40 | 2020-2025 | Sutab, Suflave |
| Evoke Pharma, INC. | $64.03 | 2021 | |
| Ferring Pharmaceuticals INC. | $58.80 | 2021-2024 | Clenpiq, Rebyota |
| Vivus LLC | $52.67 | 2025 | Qsymia, Pancreaze |
| Exact Sciences Corporation | $33.02 | 2025 | Cologuard Collection Kit |
| Ironwood Pharmaceuticals, INC | $30.63 | 2024 | |
| Romark Laboratories, Lc | $21.56 | 2020 | |
| Blueprint Medicines Corporation | $17.12 | 2022 | |
| Intercept Pharmaceuticals, INC. | $13.78 | 2025 | |
| Ipsen Biopharmaceuticals, INC | $13.77 | 2025 | Iqirvo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandhya Shukla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.